RhoA Biological Activity Is Dependent on Prenylation but Independent of Specific Isoprenoid Modification by Solski, Patricia et al.
RhoA Biological Activity Is Dependent on Prenylation but 
Independent of Specific Isoprenoid Modification1
Patricia A. Solski, Whitney Helms, Patricia J. Keely, Lishan Su, and Channing J. Der2
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, 
Departments of Pharmacology [P. A. S., C. J. D.] and Microbiology and Immunology [W. H., L. 
S.], Chapel Hill, North Carolina 27599, and Department of Pharmacology, University of Wisconsin 
Medical School and Comprehensive Cancer Center, Madison, Wisconsin 53706 [P. J. K.]
Abstract
Recent studies showed that specific isoprenoid modification may be critical for RhoB subcellular 
location and function. Therefore, we determined whether the function of the highly related RhoA 
protein is also critically dependent on specific isoprenoid modification: (a) in contrast to 
observations with RhoB or Ras proteins, where farnesylated and geranylgeranylated versions 
showed differences in subcellular location, both prenylated versions of RhoA showed the same 
plasma membrane and cytosolic location; (b) a farnesylated version of activated RhoA(63L) 
retained the same diverse functions as the normally geranylgeranylated RhoA(63L) protein, and 
both proteins show indistinguishable abilities to stimulate gene expression, cause growth 
transformation of NIH 3T3 mouse fibroblasts, to stimulate the motility of T47D human breast 
epithelial cells, and to block HIV-1 viral replication and gene expression; and (c) cells expressing 
farnesylated RhoA retained sensitivity to the growth inhibition caused by inhibition of 
geranylgeranyltransferase I, indicating that other proteins are critical targets for inhibitors of 
geranylgeranylation.
Introduction
The Rho family of small GTPases constitutes a major branch of the Ras superfamily. As 
with Ras, Rho proteins function as regulated GTP/GDP switches and cycle between an 
active GTP-bound form and an inactive GDP-bound form (reviewed in Ref. (1). To date, at 
least 18 distinct mammalian Rho family GTPases (2) have been identified and include 
RhoA, RhoB, RhoC, RhoD, RhoE/Rnd3, Rnd1, Rnd2, RhoG, Rac1, Rac2, Rac3, Cdc42, 
TTF, Chp (3), TCL (4), and Rif (5). Of these, RhoA, Rac1, and Cdc42 have been the most 
intensively studied.
Rho family GTPases are mediators of diverse cellular functions:
a. They are regulators of actin cytoskeletal organization. Whereas Cdc42 promotes 
filopodia formation, Rac1 promotes formation of lamellipodia or membrane ruffles, 
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and RhoA triggers actin stress fiber and focal adhesion formation (reviewed in 
Refs. 1, 2). In contrast, RhoE causes a disruption of stress fibers and cell rounding 
(6, 7). Consequently, Rho GTPase function can influence cell-cell and cell-
substratum interactions, which in turn can modulate cell movement. For example, 
we showed that Rac1 and Cdc42 activation promoted the motility and invasion in 
vitro of T47D human breast epithelial cells (8). Activated Rac1 promoted T-cell 
invasion in vitro (9). Overexpression of RhoC has been shown to promote the 
metastatic properties of melanoma cells in vivo (10). Thus, inhibitors of Rho 
GTPases have been considered as novel anticancer drugs (11).
b. Rho GTPases are regulators of gene expression and stimulate the activity of various 
transcription factors, including NF-κB3 (12, 13), SRF (14), and c-Jun (15, 16).
c. Rho GTPases can regulate cell cycle progression and cellular proliferation. For 
example, constitutive activation of RhoA, Rac1, and Cdc42 has been shown to 
promote tumorigenic transformation of rodent fibroblasts, and the function of these 
GTPases is required for the transforming activity of Ras and other oncoproteins 
(reviewed in Ref. 2). Finally, among a diverse spectrum of other functions, we 
determined recently that RhoA activation antagonizes HIV-1 viral replication and 
gene expression (17, 18). In light of the diverse signaling and biological activities 
of RhoA, it is not surprising that a large spectrum of functionally diverse proteins 
have been identified as downstream effector targets of RhoA (1, 2, 19).
In addition to GDP/GTP cycling, Rho GTPase function is also believed to be critically 
dependent on posttranslational modification by isoprenoid lipids. Similar to Ras, Rho 
GTPases also terminate in a COOH-terminal CAAX tetrapeptide sequence motif (where C is 
cysteine, followed by two aliphatic amino acids, ending in a variant amino acid; reviewed in 
Refs. 20, 21). This sequence signals for covalent attachment of an isoprenoid lipid group to 
the cysteine of the CAAX sequence, followed by endoprotease removal of the -AAX 
residues and carboxymethylation of the now terminal prenylated cysteine. These 
modifications promote the association of Ras and Rho GTPases with plasma and 
intracellular membranes.
The CAAX motif of Ras and Rho GTPases signal for covalent modification by either of two 
types of isoprenoid lipids (reviewed in Refs. 20, 21). The FTase enzyme catalyzes the 
addition of a C15 farnesyl group to a subset of CAAX sequences, when X is serine, 
methionine, cysteine, alanine, or glutamine. For CAAX sequences where X is leucine or 
isoleucine, the GGTaseI enzyme catalyzes addition of the more hydrophobic C20 
geranylgeranyl moiety. All isoforms of Ras are modified by farnesylation, whereas the 
closely related R-Ras and TC21/R-Ras2 proteins are modified by geranylgeranylation. A 
majority of Rho GTPases is modified by the geranylgeranyl group (e.g., RhoA, Rac, and 
Cdc42), whereas some are modified by a farnesyl group (e.g., RhoE/Rnd3; Ref. 22), and 
others can be modified by both isoprenoids (e.g., RhoB; Refs. 23, 24).
3The abbreviations used are: NF-κB, nuclear factor-κB; SRF, serum response factor; FTase, farnesyltransferase; GGTaseI, 
geranylgeranyltransferase I; FTI, farnesyltransferase inhibitor; GGTI, geranylgeranyltransferase I inhibitor; HA, hemagglutinin; GFP, 
green fluorescent protein; SRF, serum response factor; WT, wild type.
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Prenylation may critically influence subcellular location of a protein as well as regulate its 
ability to interact with other proteins. The contribution of CAAX-signaled processing to 
protein function has been best studied with Ras proteins (25–27). Mutation of the CAAX 
motif of Ras proteins prevents prenylation and abolishes plasma membrane association, 
causing a complete loss of oncogenic Ras transforming activity. This information has led to 
the development of FTIs to block Ras processing and function, and hence, are being 
developed as anticancer drugs to treat ras mutation-positive human cancers. To address the 
importance of specific isoprenoid modification for Ras function, CAAX mutants of Ras that 
undergo modification by geranylgeranylation were generated. Although the subcellular 
location of these variants was altered, with localization to intramembrane compartments, 
geranylgeranylated versions of oncogenic Ras retained potent transforming activity (28, 29). 
Therefore, it appears that oncogenic Ras function can be facilitated by modification with 
either isoprenoid group.
The importance of protein prenylation for Rho GTPase function has been best evaluated 
with RhoB. Activated RhoB can promote growth transformation, and a nonprenylated 
version of activated RhoB showed a loss of transforming activity (30, 31). However, it 
retained the ability to stimulate SRF activation. Thus, some but not all RhoB function is 
dependent on prenylation. However, in contrast to the observations with Ras, RhoB function 
appears to be critically dependent on specific isoprenoid function. RhoB appears to be 
modified primarily by farnesylation in vivo. However, FTI treatment caused an 
accumulation of geranylgeranylated RhoB (32). Prendergast and colleagues (33, 34) showed 
that geranylgeranylated RhoB inhibited the growth of rodent and human cells. Thus, 
whereas farnesylated RhoB is a growth-promoting protein, geranylgeranylated RhoB is an 
apoptosis-inducing protein. Consistent with these opposing functions, farnesylated RhoB 
function was shown to be required for Ras transformation (30), whereas geranylgeranylated 
RhoB blocked Ras transforming activity (33). Consequently, the FTI-induced formation of 
inhibitory geranylgeranylated RhoB has been proposed as the basis for the antitumor activity 
of FTIs.
RhoA and RhoB share significant sequence identity (>85%). For example, they share 
complete identity in core effector domain sequences (residues 32–40) required for 
interaction with downstream effectors. RhoA and RhoB exhibit greatest sequence 
divergence in residues immediately NH2-terminal to the CAAX motif. Because these 
sequences contain elements that influence the targeting of Ras and Rho GTPases to specific 
membrane compartments, it is not surprising that RhoA and RhoB exhibit different 
subcellular locations. One study found that only a minor fraction of RhoA was associated 
with the plasma membrane, with the majority of the protein located in the cytosol (35). In 
contrast, RhoB was associated with early endosomes and a prelysosomal compartment. 
However, a recent analysis of GFP-tagged proteins in live cells determined that RhoB was 
located predominantly at the plasma membrane, and it was suggested that the earlier 
localization of RhoB to endosomes may be an artifact of fixation (36). In contrast, RhoA 
showed a predominantly cytosolic location.
RhoA is modified exclusively by geranylgeranylation. Whether all RhoA function is 
critically dependent on prenylation and whether modification by farnesylation can support 
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RhoA function has not been determined. Additionally, pharmacological inhibitors of 
GGTaseI, the enzyme that modifies RhoA and other Rho GTPases, have been shown to 
possess antitumor activity, possibly by blocking the function of RhoA (37–40). RhoA 
function is mediated by interaction with a multitude of downstream effectors, and the 
precise location of RhoA may critically influence proper interaction with effectors (1, 2, 19). 
In the present study, we determined the requirement for modification by geranylgeranylation 
for RhoA function, whether modification by farnesylation could support the diverse 
biological functions RhoA, and whether RhoA is the critical target for GGTIs. We 
determined that RhoA function was dependent on prenylation, but that a farnesylated form 
of RhoA was unchanged in function and subcellular location. Thus, our observations 
contrast with those of RhoB and show that RhoA function is not dependent on modification 
by a specific isoprenoid. Finally, cells expressing farnesylated RhoA were still sensitive to 
growth inhibition by GGTI treatment, indicating that RhoA is not the only critical target for 
GGTIs.
Results
A Mutation in the CAAX Motif of RhoA Renders the Protein Sensitive to FTase Inhibitor 
Treatment but Does Not Alter Subcellular Location
RhoB has been found to exhibit distinct and opposing functions when modified by different 
isoprenoids (33, 34). This alteration in function has been attributed to a distinct subcellular 
location of the farnesylated and geranylgeranylated forms of RhoB. To evaluate the 
importance of prenylation for RhoA function, we generated two variants of the activated and 
transforming RhoA(63L) mutant protein:
a. The WT CAAX sequence (CLVL) was mutated to the CAAX sequence of the 
farnesylated H-Ras protein [CVLS; designated RhoA(63L)-CVLS]. This CAAX 
motif has been determined to be specific to signal for farnesylation as opposed to 
geranylgeranylation (21, 41).
b. We also generated a nonprenylated version by mutating the isoprenoid-accepting 
cysteine into a serine [SLVL; designated RhoA(63L)-SLVL]. We verified that the 
two mutant proteins were stable and could be expressed at levels comparable with 
that of the WT protein. Transiently or stably transfected NIH 3T3 cells showed that 
RhoA(63L) and RhoA(63L)-CVLS were expressed at comparable levels (Fig. 1A). 
Interestingly, in both transiently and stably transfected cells, we observed that the 
RhoA(63L)-SLVL was expressed at higher levels than RhoA(63L).
We next determined the subcellular location of the different CAAX variants of RhoA and 
then verified that the RhoA(63L)-CVLS protein was now modified by farnesylation. For 
these analyses, we generated GFP-tagged versions of each RhoA(63L) protein to evaluate 
subcellular localization in live cells. Similar to what has been described previously (35, 36), 
RhoA(63L)-WT showed both a punctate, perinuclear, and a plasma membrane staining 
distribution. GFP-tagged RhoA(63L)-CVLS showed a similar pattern and distribution (Fig. 
1B). Thus, modification by a different isoprenoid did not cause a detectable change in 
subcellular location.
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Because previous studies of RhoB localization found differences when evaluated in live 
cells when compared with fixed cells (36, 42), we also evaluated the location of HA epitope-
tagged versions of these two proteins in fixed cells (Fig. 1C). Essentially similar results were 
seen, where both WT and CVLS versions of RhoA(63L) showed punctate, perinuclear 
staining patterns. In contrast, the nonprenylated RhoA(63L)-SLVL mutant showed a diffuse 
cytoplasmic localization. We also evaluated subcellular distribution by high-speed 
fractionation into cytosolic S100 soluble and membrane-containing P100 particulate 
fractions. Both RhoA(63L)-WT and RhoA(63L)-CVLS were found predominantly in the 
P100 fraction, although RhoA(63L)-CVLS showed a reproducibly greater percentage of 
protein in the S100 fraction (data not shown). Thus, in contrast to what has been described 
for RhoB, mutation of the CAAX motif to alter the specific isoprenoid modification did not 
cause a significant change in subcellular location.
We then determined whether the distribution of the CVLS mutant was sensitive to inhibition 
by a FTI. As expected, treatment with the FTI-2153 inhibitor caused a redistribution of 
RhoA(63L)-CVLS to a diffuse cytoplasmic and nuclear location, whereas the distribution of 
RhoA(63L)-WT was unchanged (Fig. 1B). Conversely, treatment with the GGTI-2166 
GGTaseI inhibitor resulted in a diffuse distribution of RhoA(63L)-WT but did not alter the 
perinuclear distribution of RhoA(63L)-CVLS. Similar results were also seen with the HA 
epitope-tagged proteins, where RhoA(63L)-CVLS, but not RhoA(63L)-WT, was sensitive to 
FTI treatment, as measured by a change in mobility in SDS-PAGE (data not shown). We 
conclude that RhoA(63L)-CVLS is modified by farnesylation, but this alternative 
prenylation did not result in the significant change in subcellular location that has been 
described for the different prenylated forms of RhoB (32).
RhoA-mediated Transcriptional Activation of SRF, NF-κB, and the Cyclin D1 Promoter Is 
Dependent on Prenylation
Previously, it has been shown that RhoA can activate several transcription factors, such as 
SRF (14) and NF- κB (12), and can stimulate transcription from the cyclin D1 promoter 
(43). Therefore, to determine whether RhoA requires the modification by a specific prenyl 
group for activation of these factors, transient expression analyses were done using reporter 
plasmids, where expression of the luciferase gene is regulated by minimal promoters that 
contain SRF- or NF-κB-responsive elements or by the human cyclin D1 promoter. We 
found that RhoA(63L)-WT and RhoA(63L)-CVLS expression caused comparable activation 
of SRF (~ 10-fold), NF-κB (~11-fold), and cyclin D1 (~3-fold; Fig. 2). In contrast, the 
RhoA(63L)-SLVL mutant failed to cause significant stimulation in any assay. Thus, 
although prenylation is essential for the activation of these pathways, farnesylated and 
geranylgeranylated RhoA activate similar signaling pathways.
Prenylation Is Essential for the Growth-promoting Properties of RhoA(63L) but Specific 
Isoprenoid Modification Is Not
To assess the importance of prenylation in RhoA transforming activity, we analyzed the 
activity of the two mutant proteins using two transformation assays. Because Rho family 
members are weakly transforming in traditional NIH 3T3 focus assays, we and others have 
used a cooperation focus formation assay to assess the transforming activity of Rho proteins 
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and their activators (44–46). The cooperation assay allows for the synergistic enhancement 
of focus-forming ability when activated RhoA(63L) is co-expressed with a weakly 
transforming Raf-1 protein [Raf(340D)]. As we described previously, cultures transfected 
with the RhoA(63L) expression construct alone showed minimal transforming activity (< 10 
foci/dish), whereas the coexpression of RhoA(63L) with Raf(340D) resulted in a 5-fold 
above additive increase in the appearance of transformed foci (Fig. 3; Ref. 47). The 
farnesylated RhoA(63L)-CVLS mutant showed a comparable level of focus-forming 
activity, whereas the unprocessed RhoA(63L)-SLVL mutant showed greatly impaired focus-
forming activity.
Next, we determined the ability of the prenylation mutants to promote growth factor-
independent cell proliferation. Previously, we showed that RhoA(63L)-expressing NIH 3T3 
cells continue to proliferate in growth medium supplemented with low serum (44). Both the 
RhoA(63L)- and RhoA(63L)-CVLS-expressing cells retained the ability to grow in 0.5% 
serum after 21 days (Fig. 4A) and retained a refractile morphology and formed multilayered 
cultures (Fig. 4B). In contrast, both the empty vector- and RhoA(63L)-SLVL-transfected 
cells had become quiescent and formed a monolayer of non-refractile cells. These results 
demonstrate that prenylation is crucial for the growth-promoting property of RhoA(63L), 
but either isoprenoid modification could support this activity.
Prenylation Is Important for the Ability of RhoA to Promote Motility of T47D Cells
We showed previously that activated Rac1 or Cdc42 could promote increased motility and 
invasive properties of T47D human breast epithelial cells in vitro (8). Recently, we have 
also determined that activated RhoA(63L) can also cause these same changes (48).4 We 
therefore examined the importance of prenylation modification in mediating this RhoA 
function. For these analyses, we established mass populations of T47D cells stably 
transfected with expression vectors encoding each of the RhoA(63L) proteins. A comparable 
level of expression of each RhoA(63L) protein was verified by Western blot analyses (data 
not shown). As described previously, we used a haptotactic assay where transwells were 
coated on the underside of the filter with collagen. Each cell population was then plated on 
the transwell filter and allowed to migrate for 24 h through the pores of the transwell to the 
collagen-coated underside. RhoA(63L)- and RhoA(63L)-CVLS-expressing cells both caused 
an enhancement of motility across the transwell as compared with the vector control (Fig. 
5). This enhancement was not seen with cells expressing the unprenylated SLVL mutant. 
Therefore, similar to our observations with the NIH 3T3 transformation assays, activated 
RhoA(63L)-stimulated migration of T47D cells was also dependent on prenylation but could 
be facilitated by either farnesylation or geranylgeranylation.
Suppression of HIV-1 Replication by RhoA Requires Prenylation
We next wanted to determine whether geranylgeranylation of RhoA was crucial for RhoA 
inhibition of HIV-1 replication (18). For these analyses, we used two transient expression 
assays to evaluate the ability of the mutant RhoA(63L) proteins to block HIV-1 function:
4P. J. Keely, manuscript in preparation.
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a. We observed previously that the RhoA(63L) mutant inhibited HIV-1 replication, as 
measured by the production of infectious virus and of virion-associated reverse 
transcriptase activity (80 and 50% reduction, respectively). A similar level of 
inhibition was seen with the RhoA(63L)-CVLS mutant in both assays (80 and 60% 
reduction), whereas RhoA(63L)-SLVL was impaired significantly (30% reduction) 
in this ability (Fig. 6A).
b. We measured the ability of the prenylation mutants to block gene expression from 
the HIV-1 genome. These analyses used a recombinant HIV-1 virus where the 
luciferase gene is inserted in the HIV-1 Nef open reading frame (49). Similar to 
RhoA(63L), RhoA(63L)-CVLS also greatly impaired luciferase gene expression, 
whereas RhoA(63L)-SLVL showed a complete loss of this inhibitory activity (Fig. 
6B). This suggests the importance of RhoA prenylation, but not the specific 
isoprenoid modification, in mediating inhibition of HIV-1 function.
Farnesylated RhoA Does Not Protect Cells from Growth Inhibition Caused by Inhibition of 
GGTaseI
Pharmacological inhibition of GGTaseI has been shown to inhibit normal and tumor cell 
proliferation, in part by blocking progression through G1 of the cell cycle (50). Rho 
GTPases are substrates for GGTaseI and have been shown to be required for proliferation 
through G1 (51, 52). Hence, geranylgeranylated Rho GTPases constitute logical targets for 
the inhibitory action of GGTIs. One approach for evaluating this possibility is to determine 
whether variants of Rho GTPases that are insensitive to GGTIs can protect cells from GGTI 
growth inhibition. In this study, we have shown that farnesylation can support the diverse 
signaling and biological functions of RhoA. Thus, this farnesylated variant of RhoA can 
serve as a useful reagent to evaluate whether RhoA is a critical target of GGTIs.
To determine whether RhoA is an important target for the inhibitory activity of GGTIs, we 
compared the sensitivity of NIH 3T3 cells stably expressing RhoA(63L)-WT and 
RhoA(63L)-CVLS. Similar to what has been described previously, treatment of cells 
expressing RhoA(63L)-WT with GGTI-2166 caused a dose-dependent inhibition of 
proliferation. RhoA(63L)-WT expressing cells cultured in growth medium supplemented 
with 3 μm GGTI-2166 showed an ~30% reduction in cell number and an ~80% reduction at 
10 μm GGTI-2166 (Fig. 7). Essentially identical levels of growth inhibition was seen with 
RhoA(63L)-CVLS-expressing cells. Thus, the growth-inhibitory activity caused by GGTI 
treatment is not attributable solely, if at all, to the loss of RhoA function.
Discussion
Ras and Rho small GTPases undergo posttranslational modification by either the C15 
farnesyl or C20 geranylgeranyl isoprenoid groups in reactions that are catalyzed by distinct 
but structurally related enzymes, FTase and GGTaseI, respectively (21, 25, 41). Whether 
protein function is uniquely influenced by modification by a specific isoprenoid remains 
incompletely understood. Recent studies suggest that RhoB function is greatly altered by the 
type of isoprenoid modification it undergoes (33, 34). Whereas farnesylated RhoB exhibits a 
growth-promoting function, geranylgeranylated RhoB exhibited a growth-inhibitory, 
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apoptotic activity. These observations prompted us to evaluate whether the function of the 
closely related RhoA protein is also greatly influenced by specific isoprenoid modification. 
We found that a farnesylated version of activated RhoA(63L) retained the abilities to cause 
growth transformation of NIH 3T3 cells, to stimulate transcription factor activity, to 
promote T47D breast carcinoma migration, and to block HIV-1 replication and gene 
expression. Conversely, a nonprenylated form of RhoA(63L) showed a loss of all function. 
Thus, we conclude that RhoA function is dependent on prenylation but independent of 
specific isoprenoid modification. Additionally, because cells expressing farnesylated RhoA 
retained sensitivity to growth inhibition by GGTaseI inhibition, other GGTaseI substrates 
must also be important targets for GGTaseI inhibitors.
Our analyses of the role of isoprenoid modification on RhoA function extend on previous 
studies that address whether specific isoprenoid modification is critical for protein function. 
Approximately 0.5% of mammalian proteins undergo posttranslational modification by 
isoprenoid lipids, and of the two types of prenylation, geranylgeranylation is the 
predominant modification (21, 25). Interestingly, proteins that are both structurally and 
functionally related can be modified by different isoprenoid moieties. For example, the three 
Ras isoforms (H-Ras, K-Ras, and N-Ras) are all modified by farnesylation, whereas the 
closely related R-Ras1 and R-Ras2/TC21 proteins are modified by geranylgeranylation. 
However, despite differences in isoprenoid modification, constitutively activated mutants of 
Ras and R-Ras isoforms all cause growth transformation. Similarly, whereas RhoA is 
modified by geranylgeranylation, the related RhoE protein is modified by farnesylation (22). 
In this case, though, these proteins have opposing functions, with RhoA promoting actin 
stress fiber formation and RhoE causing a disruption of stress fibers. Whether the different 
prenylated nature of these two proteins accounts for their opposing functions has not been 
determined. The γ subunits of heterotrimeric G proteins are also modified by prenylation. 
Among the 11 known γ subunits, γ1, γ8, and γ11 are farnesylated, whereas the remaining 
subunits are modified by geranylgeranylation (53). When analyzed, no striking isoprenoid-
specific differences in γ subunit function has been found. Thus, to date, studies evaluating a 
role for specific isoprenoid modification in protein function have determined surprisingly 
subtle or no differences in isoprenoid regulation of protein function (29, 54, 55).
Our observations that RhoA transforming activity could be mediated by geranylgeranylation 
as well as farnesylation contrasts sharply with the observations made with RhoB. Whereas 
farnesylated RhoB was found to exhibit a growth-promoting activity that was required for 
Ras transformation, geranylgeranylated RhoB instead showed a proapoptotic function that 
antagonized Ras transformation (33, 34). These strikingly different consequences of 
different isoprenoid modifications on RhoA and RhoB function are unexpected in light of 
their strong structural (>85% amino acid sequence identity) and functional (e.g., promotion 
of actin stress fibers) similarities. However, RhoA and RhoB diverge significantly in their 
COOH-terminal sequences and consequently do localize to very distinct regions in the cell. 
This may account for the different consequences of isoprenoid modification on RhoA and 
RhoB biological activity.
Our observations with RhoA transformation are similar to previous observations that 
geranylgeranylated versions of oncogenic H-Ras proteins also retained the ability to cause 
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transformation (29). However, we also found that a geranylgeranylated mutant of WT H-Ras 
was growth inhibitory. This result suggests that specific isoprenoid modification is 
important for the normal function of H-Ras. Whether normal RhoA function is also 
dependent of specific isoprenoid modification remains to be determined. Finally, it will be 
important to determine whether the function of other Rho GTPases will be dependent (i.e., 
RhoB) or independent (i.e., RhoA) of specific isoprenoid modification.
RhoA function is mediated by interaction with a large number of functionally diverse 
effectors. The precise effector(s) important for mediating the ability of RhoA to cause 
growth transformation of NIH 3T3 cells, motility of T47D cells, and to block HIV-1 
function remain to be determined. However, our analyses of a panel of effector domain 
mutants of activated RhoA(63L),5 which are impaired differentially in effector interactions, 
indicate that these three RhoA functions are initiated through the use of different effectors. 
Our observation that nonprenylated RhoA(63L) was deficient in all three activities indicates 
that membrane association is essential for RhoA interaction with the effectors involved in 
these processes. Finally, we found that RhoA activation of SRF was also dependent on 
prenylation. This result contrasts with the observation that nonprenylated RhoB can still 
activate SRF and further suggests that the distinct subcellular locations of RhoA and RhoB 
must greatly influence their functions (31).
During the course of our studies, Allal et al. (56) published a study showing that the 
function of activated RhoA was also independent of the type of isoprenoid modification. 
They determined that farnesylated RhoA(14V) was unchanged in subcellular location, 
interaction with RhoGDI, actin reorganization, growth transformation of NIH 3T3 cells, 
suppression of p21CIP1 gene expression, and stimulation of SRF. Thus, our observations are 
in agreement with and extend their observations to other biological functions of RhoA. We 
showed additionally that farnesylation can support two other diverse RhoA-mediated 
functions, induction of breast tumor cell migration in vitro and RhoA inhibition of HIV-1 
function. Hence, it appears that the majority of RhoA effector function can be supported by 
either isoprenoid modification. Because a goal of our studies was to use farnesylated RhoA 
to evaluate the mechanism of GGTI-mediated growth inhibition, a complete evaluation of 
whether diverse functions of RhoA can be supported by alternative prenylation is critical. 
Additionally, because there are currently conflicting observations regarding whether RhoB 
function is dependent on a specific isoprenoid (33, 57), independent studies that show that 
RhoA function can be supported by modification by either isoprenoid is important.
Pharmacological inhibitors of GGTaseI have been developed as potential anticancer drugs 
(11) and have shown potent antitumor activity in cell culture and animal preclinical studies. 
The mechanism of growth inhibition of GGTIs has been ascribed, in part, to inhibition of 
progression through G1 of the cell cycle (50). Because RhoA, a GGTaseI substrate, has been 
shown to be critical for G1 progression (51, 52), it represents a possible target for GGTI-
induced growth inhibition. In the present study, we established that farnesylated RhoA 
retained all signaling and biological functions of the authentic geranylgeranylated RhoA 
protein. This provided important validation that farnesylated RhoA will be a useful RhoA 
5P. A. Solski and C. J. Der, manuscript in preparation.
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variant to determine whether RhoA is indeed the critical target for GGTIs. However, we 
found that NIH 3T3 cells stably expressing farnesylated RhoA showed the same sensitivity 
to GGTI-induced growth inhibition. Although this result does not eliminate RhoA as a 
critical target, it does indicate that other GGTaseI substrates must also be involved in GGTI 
growth inhibition. Logical candidates include two other Rho GTPases, Rac1 and Cdc42, that 
are substrates for GGTaseI and have also been shown to be required for G1 progression. 
Because loss of function of RhoA, Rac1, or Cdc42 alone was sufficient to block G1 
progression, perhaps GGTI-mediated loss of function of all three Rho GTPases is 
responsible for GGTI growth inhibition. To evaluate this possibility, it must first be 
determined whether farnesylated versions of Rac1 and Cdc42 also retain the same functions 
as their authentic geranylgeranylated counterparts. If so, then it will be important to 
determine whether coexpression of farnesylated RhoA, Rac1, and Cdc42 can reduce the 
sensitivity of cells to GGTI-induced growth inhibition. If not, then other GGTaseI substrates 
must be targeted by GGTIs to cause growth inhibition. The identity of these 




To generate cDNA sequences encoding mutants of activated RhoA(63L) that undergo 
modification by a farnesyl isoprenoid [designated RhoA(63L)-CVLS] or is nonprenylated 
[designated RhoA(63L)-SLVL], we introduced missense mutations into the sequence that 
encodes the COOH-terminal CAAX motif. cDNA sequences encoding the CAAX mutations 
(CVLS and SLVL) were generated by using the QuikChange Site-Directed Mutagenesis kit 
(Stratagene) and the cDNA sequence for RhoA(63L) in the pBS(HA)rhoA(63L) plasmid as 
a template for mutagenesis. RhoA(63L)-CVLS terminates with the CAAX tetrapeptide 
sequence of the farnesylated H-Ras protein. RhoA(63L)-SLVL contains a cysteine-to-serine 
substitution in the RhoA CAAX motif to remove the site of prenylation addition. The 
template pBS(HA)rhoA(63L) was constructed first by inserting a DNA linker that encoded 
the HA epitope (YPYDVPDYA) into the BamHI site of pBluescript II(KS) (Stratagene), 
resulting in pBS(HA). The linker also contained an internal NdeI site in-frame and 3’ of the 
HA epitope tag. The NdeI-EcoRI fragment from pcDNA3rhoA(63L) (Ref. 43; which also 
contains a BamHI site 3’ of the coding sequence) was inserted into the NdeI-EcoRI sites of 
pBS(HA). All constructs were then confirmed by sequencing. The BamHI fragment from 
each of the mutated pBS(HA)rhoA(63L) constructs was inserted into the BamHI site of the 
pZIP-NeoSV(x)1 retrovirus mammalian expression vector (58) and the pcDNA3 
mammalian expression vector (Invitrogen). The pZIP-raf(340D) plasmid encodes a weakly 
activated mutant of human Raf-1 and has been described previously (44). Mammalian 
expression vectors encoding GFP-tagged fusion proteins of RhoA(63L)-WT, RhoA(63L)-
CVLS, and RhoA(63L)-SLVL were generated by insertion of the BamHI fragment from the 
pBS(HA)rhoA(63L) constructs into the BamHI site of pEGFP-C1 (Clontech).
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Cell Culture, Transfection, and Transformation Assays
NIH 3T3 mouse fibroblasts were maintained in DMEM supplemented with 10% calf serum 
(Hyclone). Human embryonic kidney 293T cells and the HeLa-MAGI human cervical 
carcinoma cells were maintained in DMEM supplemented with 10% FCS (Life 
Technologies, Inc.). T47D human breast epithelial cells were grown in RPMI supplemented 
with 10% FCS and 0.2 units/ml insulin. For cooperation focus formation assays with 
Raf(340D), NIH 3T3 cells were transfected by the calcium phosphate precipitation along 
with a glycerol shock as described previously (47). For these transfections, 1 μg of the pZIP-
rhoA and 1 μg of pZIP-raf(340D) plasmid DNA were cotransfected into NIH 3T3 cells. 
Twenty-one days after transfection, the dishes were stained with crystal violet, and the 
appearance of foci of transformed cells was quantitated by visual inspection.
To establish cell lines stably expressing WT or mutant RhoA(63L) protein, NIH 3T3 were 
transfected by calcium phosphate precipitation as above with 500 ng of the pZIP-NeoSV(x)1 
retrovirus expression vector constructs. Three days after transfection, the transfected 
cultures were subcultured at a 1:5 split ratio into growth medium supplemented with 400 
μg/ml of G418. Mass populations of G418-resistant colonies were pooled together to 
establish cell lines that were then used for GGTI sensitivity experiments, growth 
transformation assays, and immunofluorescence analysis for determination of protein 
location. Western blot analyses with anti-HA antibody (Covance) were done to verify that 
there was comparable expression of each RhoA(63L) protein in the established cell lines.
To evaluate the ability of each cell line to proliferate in growth medium supplemented with 
low serum, three dishes were plated with 103 cells/60-mm dish and were allowed to attach in 
growth medium. After 16 h, the growth medium was replaced with DMEM supplemented 
with 0.5, 2, or 10% calf serum. The dishes were cultured for 21 days, and the appearance of 
colonies of proliferating cells was visualized by staining with 0.4% crystal violet.
To evaluate the ability of each cell line to proliferate in growth medium supplemented with 
GGTI-2166 GGTI (FTI-277, FTI-2153, GGTI-298, and GGTI-2166 provided by Said Sebti 
and Andrew Hamilton; Ref. 59), NIH 3T3 cells stably expressing the WT and CVLS 
versions of RhoA(63L) proteins were plated at 103 cells/35-mm dishes in growth medium. 
After 18 h, normal growth medium was replaced with growth medium supplemented with 
either vehicle (DMSO), 3, or 10 μm GGTI-2166. Every 24 h, the medium was replaced with 
fresh vehicle/GGTI-containing medium. On days 3, 5, 6, 8, 10, and 12, the cells from two 
dishes were trypsinized and were counted on a hemacytometer for each condition.
Transient Expression Reporter Gene Assays
For the transcriptional activation assay, 293T cells were transfected by calcium phosphate 
coprecipitation as described above except that the glycerol shock was excluded. Five 
hundred ng of the pcDNA-rhoA plasmid DNA or pcDNA3 empty vector were cotransfected 
together with 2 μg of the luciferase gene reporter plasmids, where expression is controlled 
by a minimal promoter from the c-fos gene that contains multiple SRF (43) or NF-κB (60) 
responsive DNA elements. The cyclin D1-Luc plasmid contains the luciferase gene under 
the control of the human cyclin D1 promoter (61). Twenty-four h after transfection, the 
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growth medium was replaced with DMEM supplemented with 0.5% FCS. After 16–20 h, 
the cells were lysed and then analyzed for luciferase activity using enhanced 
chemiluminescence and a Monolight 2010 luminometer (Analytical Luminescence).
Cell Migration Assays
Migration assays were performed as described previously (48). T47D cells were stably 
transfected with pZIP-NeoSV(x)1 plasmid DNA encoding the parental RhoA(63L) protein 
and the two CAAX mutants and selected in growth medium supplemented with 300 μg/ml 
G418. For the migration assay, transwell dishes (12-well cluster, 12 mm diameter, 12 μm 
pore size; Costar) were coated from the underside with 3 μg/ml collagen I in water 
(Collaborative Biomedical Products), and serum-free RPMI was placed in the lower 
chamber. Motility was assessed by adding 104 cells in the upper chamber of the transwell in 
RPMI supplemented with 5 mg/ml BSA. The transwells were incubated in a humidified CO2 
incubator (10%) at 37°C for 16 h. The nonmotile cells were then removed from the upper 
chamber, and the transwell filter was fixed and stained with Wright-Giemsa stain 
(Diffquick; Baxter) and then removed and mounted on a microscope slide with Cytoseal 
(Baxter) solution and a coverslip. The number of remaining cells, which represent the motile 
cells, were counted on a Nikon microscope.
Localization Analyses
The subcellular locations of CAAX mutants of RhoA were determined in both live and fixed 
cells. For live cell analyses, NIH 3T3 cells plated on coverslips in 6-well dishes were 
transiently transfected (Lipofectamine-Plus; Life Technologies, Inc.) with expression 
vectors encoding GFP-tagged RhoA(63L) proteins. Twenty-four h after transfection, the 
coverslips were washed twice with PBS and inverted onto microscope slides. Live cells 
were examined with a Axioskop 2 fluorescence microscope (Zeiss) and Openlab digital 
imaging software (Improvision). To evaluate the sensitivity of prenylation-dependent 
subcellular localization, cells expressing RhoA(63L)-WT and RhoA(63L)-CVLS proteins 
were treated with FTase and GG-Tase inhibitors. For these analyses, cells transiently 
expressing the GFP-tagged proteins were incubated for 24 h with growth medium 
supplemented with either vehicle (DMSO), 10 μM FTI-2153, or 10 μm GGTI-2166.
For our second approach to evaluate subcellular location of the RhoA mutant proteins, NIH 
3T3 cells stably expressing HA epitope-tagged WT and mutated RhoA(63L) proteins were 
plated onto coverslips and incubated overnight in growth medium. The cells were then fixed 
in 3.7% formaldehyde in PBS for 10 min and incubated for 30 min in PBS supplemented 
with 0.1% Triton X-100 and 5 mg/ml BSA. The HA epitope-tagged RhoA(63L) proteins 
were visualized by indirect immunofluorescence using an anti-HA antibody, followed by a 
FITC-conjugated goat antimouse secondary antibody (Jackson Immunoresearch 
Laboratories).
Analysis of HIV-1 Replication and Gene Expression
Inhibition of HIV-1 replication was assessed by cotransfection of the HIV-1 proviral 
genome pNL4–3 with each pcDNA-rhoA plasmid DNA into 293T cells using Effectene 
(Qiagen) as reported previously (18). Infectious units and virion-associated reverse 
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transcriptase activity in culture supernatant were determined by titering on HeLa-MAGI 
cells at 48 h after transfection as described previously (62). A pAX142-lacZ reporter 
plasmid, where the lacZ gene is expressed constitutively from the EF1 α promoter, was also 
cotransfected, and β-galactosidase activity was measured to confirm similar transfection 
efficiency. Inhibition of the HIV-1 gene expression in human T cells (Jurkat) was analyzed 
by cotransfecting (Superfect; Qiagen) pcDNA-rhoA plasmid DNA together with pNL4-Luc 
(49), where the luciferase gene was under control of the HIV-1 long terminal repeat 
promoter. Forty-eight h after transfection, cells were lysed, and luciferase activity was 
determined as described (18).
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Substitution of the CAAX motif of RhoA(63L) with the CVLS motif from farnesylated H-
Ras results in a protein that is not altered in subcellular location but is sensitive to FTase, but 
not GGTaseI, inhibitor treatment. A, lysates from NIH 3T3 cells stably or transiently 
expressing HA epitope-tagged RhoA(63L) proteins were normalized for total protein. The 
proteins were resolved by SDS-PAGE, and expression was determined by Western blot 
analysis using anti-HA epitope antibody. B, NIH 3T3 cells transiently expressing the 
indicated GFP-tagged RhoA(63L) proteins were cultured in growth medium supplemented 
with vehicle (DMSO), FTI-2153, or GGTI-2166 were analyzed as live cells. Cells were then 
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visualized using a Axioskop 2 microscope and Openlab digital imaging software. C, 
alternatively prenylated, but not unprenylated, shows a similar subcellular location as 
geranylgeranylated RhoA(63L). NIH 3T3 cells stably expressing HA epitope-tagged 
RhoA(63L)-WT, RhoA(63L)-CVLS, and RhoA(63L)-SLVL were fixed, and the proteins 
were visualized by indirect immunofluorescence analyses using anti-HA epitope antibody 
and a FITC-conjugated antimouse secondary antibody. Data shown are representative of 
three independent experiments.
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Farnesylated, but not unprenylated, RhoA(63L) retains the ability to stimulate 
transcriptional activation of SRF and NF-κB and the cyclin D1 promoter. 293T cells were 
transiently cotransfected with pcDNA3 expression plasmids encoding the indicated proteins 
(500 ng/30-mm dish) together with reporter plasmids, where the luciferase gene is under 
control of the fos minimal promoter containing either SRF (A)- or NF-κB (B)-responsive 
elements or the human cyclin D1 promoter (C). Forty-eight h after transfection, stimulation 
of transcriptional activity was determined by measuring luciferase activity of cell lysates. 
Fold activation was determined by the number of relative luciferase units relative to the 
number of units seen with the empty vector control. Data points are the means of three 
independent measurements; bars, SE. Data are representative of three independent assays.
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Farnesylated, but not unprenylated, RhoA(63L) retains potent focus-forming activity. NIH 
3T3 cells were cotransfected with pZIP-NeoSV(x)1 expression plasmids encoding the 
indicated RhoA(63L) proteins, either together with the empty pZIP-NeoSV(x)1 vector (–) or 
with pZIP-raf(340D) (1 μg/60-mm dish). Seventeen to 21 days after transfection, the 
number of foci of transformed cells was quantified. Data points are the means of three 
independent measurements; bars, SE. Data are representative of three independent assays.
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Farnesylated, but not unprenylated, RhoA(63L) retains the ability to promote growth in low 
serum. NIH 3T3 cells stably expressing RhoA(63L)-WT, RhoA(63L)- CVLS, or 
RhoA(63L)-SLVL were plated at 103 cells/dish and allowed to adhere in DMEM 
supplemented with 10% calf serum. Untransformed cells stably transfected with the empty 
pZIP-NeoSV(x)1 plasmid (Vector) were included as a control. After 24 h, the medium was 
replaced with DMEM supplemented with 0.5% calf serum. Twenty-one days after plating, 
the cells were fixed and stained with 0.4% crystal violet (A) to better visualize the cells. On 
day 20, the cells were photographed (B) to demonstrate the different morphology of the 
cells.
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RhoA(63L)-induced migration of T47D human breast carcinoma cells is dependent on 
prenylation, but not specific prenylation. T47D cells stably expressing the indicated protein 
were analyzed for their ability to migrate through the pores of a transwell to the underside. 
Fold activation was determined by the number of migrating cells relative to the number of 
migrating vector-transfected cells. Western blot analyses with anti-HA epitope antibody was 
done to verify equivalent expression of RhoA(63L) protein in each cell population; although 
WT and CVLS versions of RhoA(63L) showed comparable levels of expression, the SLVL 
mutant consistently showed slightly higher levels of expression in this and other analyses 
(not shown). Data points are the means of two independent measurements; bars, SE. Data 
shown are representative of three independent assays.
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Farnesylated, but not unprenylated, RhoA(63L) retains the ability to antagonize HIV-1 
replication and gene expression. A, the ability of the RhoA(63L) protein to block the 
transient replication of HIV-1 was assessed by cotransfecting the HIV-1 provirus pNL4–3 
with pcDNA3 expression plasmids encoding the indicated proteins in 293T cells. At 40–50 
h after transfection, HIV-1 virions in the culture supernatant were measured by reverse 
transcriptase activity (□) or by quantification of infectious units (■). The relative HIV-1 
replication is presented as a percentage of vector controls (100%). B, the ability of 
RhoA(63L) protein to inhibit gene expression was assessed by cotransfecting pNL4–3-
Luciferase plasmid with pcDNA3 expression plasmids encoding the RhoA proteins in Jurkat 
T cells. The level of luciferase expression (relative light units) was measured 48 h after 
transfection. Data points are the means of three independent measurements; bars, SE. Data 
shown are representative of two independent experiments.
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Cells expressing farnesylated RhoA are still sensitive to growth inhibition by inhibition of 
GGTaseI. Cultures of NIH 3T3 cells stably expressing RhoA(63L)-WT or RhoA(63L)-
CVLS were incubated with growth medium supplemented with 3 or 10 μm GGTI-2166. Cell 
number was determined on days 3, 5, 6, 8, 10, and 12, with data shown for day 12, are the 
average of duplicate dishes and are representative of three independent experiments; bars, 
SE.
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